ShiveringPhase 4NCT05284409
Comparative Study Between the Prophylactic Intravenous Administrations of Acetaminophen vs Dexamethasone vs Pethidine Regarding the Incidence of Shivering Induced by Single Shot Spinal Anesthesia in the Orthopedic Surgeries of the Lower Limbs
A Phase 4 study testing Pethidine, Acetaminophen and Dexamethasone in people with Shivering, run by Ain Shams University at 1 site in Egypt.
Trial summary
Single Shot Spinal anesthesia (SSSA) is associated with considerable perioperative shivering and can be challenging to treat. Some pharmacologic agents like N-methyl d-aspartate receptor antagonists, magnesium sulfate and opioid analgesics have been used for restriction of post-spinal anesthesia shivering. Read more about this study
- Who is it for?
- Ages 20 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Shivering
- What is being tested?
- Pethidine, Acetaminophen and Dexamethasone
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 130 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Jul 2022to 1 Oct 2022
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- American Society of Anesthesiologists physical status (ASA) I or II.
- Both sexes.
- Age ranging from 20 to 55 years old.
- Body weight ranging from 60 to 100 kilograms.
- Receiving Single Shot Spinal anesthesia.
- Scheduled for orthopedic surgeries of the lower limb.
Who cannot join
- Patient's refusal.
- Allergy to local anesthetics or any of the studied drugs.
- Patients with significant cognitive dysfunction.
- Duration of surgery more than 120 min.
- Patients with hypo- or hyperthyroidism.
- An initial body temperature >38.0 or <36.0 degree Celsius.
Show all 10Show fewer
- Receiving vasodilators, or medications likely to alter thermoregulation.
- Pregnancy.
- Sensory blockade level reaching T4 or higher.
- Obesity (BMI > 35 kg/m2).
Trial locations and contacts
1 site in 1 country.
About this study
Single Shot Spinal anesthesia (SSSA) is associated with considerable perioperative shivering and can be challenging to treat. Some pharmacologic agents like N-methyl d-aspartate receptor antagonists, magnesium sulfate and opioid analgesics have been used for restriction of post-spinal anesthesia shivering. Besides that shivering is poorly understood, the gold standard for the treatment and prevention has not been defined yet.
This study is to determine the effect of prophylactic intravenous administration of acetaminophen versus dexamethasone versus pethidine in controlling shivering induced by spinal anesthesia
Read the detailed description
Aim of this study is to compare between the prophylactic intravenous administrations of acetaminophen vs dexamethasone vs pethidine regarding the incidence of shivering induced by single shot spinal anesthesia in the orthopedic surgeries of the lower limbs
Ethical Considerations: Approval of the research ethical committee of the faculty of medicine, Ain Shams University will be obtained and informed written consents will be taken from all the participants after full clarification of the study and their rights for withdrawal at any time will be assured and their privacy will be guaranteed. The single shot spinal anesthesia technique will be performed by a single experienced anesthetist.
Study tools: Bedside Shivering Assessment Scale (BSAS) to indicate the degree of shivering at the time of its onset either intra or postoperatively, and throughout the duration of one hour at the post-anesthesia care unit (PACU).
Study Interventions: The study will include 108 patients fulfilling the inclusion criteria undergoing orthopedic surgeries of the lower limbs. The patients will be randomized into three equal groups by a computer-generated table of random numbers, each including 36 patients, namely groups A, B, and C according to the drug used as an anti-shivering agent. The assigned medication will be prepared in a color coded 250 ml polypropylene bottle of normal saline. The administration of the assigned infusion will be done by a resident not involved in the study after stabilization of the sensory blockade level over a duration of 15 to 20 minutes, the study drugs will be prepared by the hospital pharmacy and follow-up of the patients will be conducted by the anesthesia residents not involved in any other part of the study.
Group A: (control group) 36 patients will receive 0.5 mg/kg Pethidine IVI for management of shivering induced by Single Shot Spinal Anesthesia.
Group B: 36 patients will receive 15 mg/kg Acetaminophen IVI for management of shivering induced by Single Shot Spinal Anesthesia.
Group C: 36 patients will receive 0.1 mg/kg Dexamethasone IVI for management of shivering induced by Single Shot Spinal Anesthesia.
All patients will be assessed preoperatively, and will be instructed to fast for 6 hours.
On arrival to the operating theatre, all patients will have an inserted peripheral wide bore IV access (18 G). Anti-stress measures: intravenous pantoprazole 40 mg will be given. I.V. fluids will be preheated to room temperature. Lactated Ringer's solution will be infused at 10 ml/kg over 30 min before spinal anesthesia. The infusion rate will then be modified according to the intraoperative fluid balance.
Conventional monitoring including electrocardiogram (ECG), heart rate (HR), non-invasive blood pressure (NIBP) and pulse oximetry (SPO2) will be conducted. Hemodynamic readings (Mean arterial blood pressure (MAP), HR, and SPO2), peripheral and room temperatures will be recorded before the administration of the single shot spinal anesthesia. The operating and recovery rooms temperatures will be maintained at 25°C±1 with approximately 60% humidity.
Preoperatively, all of the patients will receive titration of 0.5 mg Midazolam increments on intravenously as an anesthetic adjuvant. Anesthetic equipment and drugs for resuscitation will be kept ready at hand before starting the spinal anesthesia. Supplemental oxygen (6 liter/min) will be administered via a facemask during the operation.
The patients in all of the groups will receive SSSA. The blocks will be performed by well trained personnel. The blocks will be performed before administration of the compared medications after obtaining intravenous (IV) access and application of standard ASA monitoring. Under complete aseptic conditions, single shot spinal anesthesia will be instituted at either L3/4 or L4/5 interspaces. 2.8 mL (14 mg) of 0.5% hyperbaric bupivacaine at a rate of 0.2 ml/sec will be injected in the sitting position by an anesthetist who was blind to the study by using 25 gauge Quincke spinal needle. The patient will be placed in the Supine position. The sensory blockade level will be checked in order not to reach the level of T4.
Sensory levels will be assessed by pinprick test to determine the peak sensory level and time to two segment regression in minutes. Motor block will be assessed by using Modified Bromage scale (16) (0 = no block 1 = hip block, 2 = hip and knee block, 3 = hip, knee, and ankle block) to determine the time to reach complete motor block and duration of motor blockade (in minutes).
The desired motor and sensory block will be Bromage scale 3 and T6, respectively.
All of the patients will be covered with one layer of surgical drapes over the chest, thighs, and calves during the operation and one cotton blanket over the entire body after operation. Assessment parameters: HR, MAP, and SPO2 will be recorded using standard non-invasive monitors before intrathecal injection and thereafter at 5, 10, 15, 20 minutes then every 10 minutes to complete 90 minutes from the intrathecal injection.
All of the patients will be observed for: Hypotension (defined as a decrease in MAP of more than 20% from baseline or a decrease of the systolic arterial blood pressure below 90 mmHg and baseline MAP will be calculated from three measurements taken in the ward before the operation) will be treated by crystalloid infusion and if necessary ephedrine 5 mg IV will be administered. The amount of ephedrine given in each group will be recorded. Bradycardia will be considered if the heart rate is less than 50 beats/min and will be treated with IV atropine (0.01mg/kg).
Pruritus will be assessed by a four-point ordinal scale where zero points to no itching, one points to mild itching, two points to moderate itching, treatment not requested, three points to severe itching, treatment requested.
In case of pruritus (45.5 mg intramuscular pheniramine hydrogen maleate) will be given.
The administration of the assigned infusion will be done by a resident not involved in the study after stabilization of the sensory blockade level over the duration of 15 to 20 minutes.
The level of sedation will be assessed according to a five-point range: [1] alert and oriented, [2] somnolent, [3] closed eyes, arousable on a verbal order, [4] closed eyes, arousable to physical stimuli and [5] closed eyes and patient unarousable to physical stimuli.
Body temperature (axillary temperature) will be recorded with a percutaneous thermometer. The ambient temperature will be measured by a wall thermometer. The ambient temperature will be maintained at 25 degree Celsius with constant humidity. Fluid management intraoperatively will be done according to bodyweight of the patient and intra-operative losses.
When shivering occurs, it will be graded using Bedside Shivering Assessment Scale (BSAS): 0 - None: No Shivering, 1 - Mild: Shivering localized to neck/thorax, maybe seen only as artifact on ECG or felt by palpation 2 - Moderate: Intermittent involvement of the upper extremities +/- thorax 3 -Severe: Generalized shivering or sustained upper / lower extremity shivering.
In all of the groups, the degree of shivering will be assessed at the time of its onset either intra or postoperatively, and throughout the duration of one hour at the post-anesthesia care unit (PACU). Grade 3 or 4 of shivering score will be regarded as failure of prophylaxis, and a rescue dose of 0.2 mg/kg Pethidine IV will be administered and the total dose will be recorded.
Patients will be admitted to the PACU. Patient's satisfaction will be assessed by asking the patient to answer the question, "How would you rate your experience after the operation?" using a 7-point Likert verbal rating scale, and acceptable satisfaction score of the patient will range from 5 to 7 (1 - Extremely dissatisfied, 2 - Dissatisfied, 3 - Somewhat dissatisfied, 4 - Undecided, 5 - Somewhat satisfied, 6 - Satisfied, 7 - Extremely satisfied).
- Conditions
- Shivering
- Being tested
- Pethidine, Acetaminophen, Dexamethasone
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PethidineDrug
36 patients will receive 0.5 mg/kg Pethidine IVI
AcetaminophenDrug
36 patients will receive 15 mg/kg Acetaminophen IVI
DexamethasoneDrug
36 patients will receive 0.1 mg/kg Dexamethasone IVI
| Study group | Role | What they receive |
|---|---|---|
| Pethidine | Active comparator | (control group) 36 patients will receive 0.5 mg/kg Pethidine IVI for management of shivering induced by Single Shot Spinal Anesthesia. Receives: Drug: Pethidine |
| Acetaminophen | Experimental | 36 patients will receive 15 mg/kg Acetaminophen IVI for management of shivering induced by Single Shot Spinal Anesthesia. Receives: Drug: Acetaminophen |
| Dexamethasone | Experimental | 36 patients will receive 0.1 mg/kg Dexamethasone IVI for management of shivering induced by Single Shot Spinal Anesthesia. Receives: Drug: Dexamethasone |
What is being measured
The primary outcome is the main question the study is designed to answer.
The incidence of shivering
The incidence of shivering induced by single shot spinal anesthesia after the prophylactic administration of the study medications.
When shivering occurs, it will be graded using Bedside Shivering Assessment Scale (BSAS): 0 - None: No Shivering, 1 - Mild: Shivering localized to neck/thorax, maybe seen only as artifact on ECG or felt by palpation 2 - Moderate: Intermittent involvement of the upper extremities +/- thorax 3 -Severe: Generalized shivering or sustained upper / lower extremity shivering.
In all of the groups, the degree of shivering will be assessed at the time of its onset either intra or postoperatively, and throughout the duration of one hour at the post-anesthesia care unit (PACU). Grade 3 or 4 of shivering score will be regarded as failure of prophylaxis, and a rescue dose of 0.2 mg/kg Pethidine IV will be administered and the total dose will be recorded.
Measured: During procedure to up to one hour at the post-anesthesia care unit (PACU)
Secondary outcomes (5)
The need to administer pethidine
In all of the groups, the degree of shivering will be assessed at the time of its onset either intra or postoperatively, and throughout the duration of one hour at the post-anesthesia care unit (PACU). Grade 3 or 4 of shivering score will be regarded as failure of prophylaxis, and a rescue dose of 0.2 mg/kg Pethidine IV will be administered.
Measured: The time of administration of pethidine
the total dose of Pethidine given
In all of the groups, the degree of shivering will be assessed at the time of its onset either intra or postoperatively, and throughout the duration of one hour at the post-anesthesia care unit (PACU). Grade 3 or 4 of shivering score will be regarded as failure of prophylaxis, and a rescue dose of 0.2 mg/kg Pethidine IV will be administered and the total dose will be recorded.
Measured: The time of administration of pethidine
The patient's satisfaction
Patient's satisfaction will be assessed by asking the patient to answer the question, "How would you rate your experience after the operation?" using a 7-point Likert verbal rating scale, and acceptable satisfaction score of the patient will range from 5 to 7 (1 - Extremely dissatisfied, 2 - Dissatisfied, 3 - Somewhat dissatisfied, 4 - Undecided, 5 - Somewhat satisfied, 6 - Satisfied, 7 - Extremely satisfied).
Measured: up to one hour postoperative
The level of sedation
The level of sedation will be assessed according to a five-point range: [1] alert and oriented, [2] somnolent, [3] closed eyes, arousable on a verbal order, [4] closed eyes, arousable to physical stimuli and [5] closed eyes and patient unarousable to physical stimuli.
Measured: within 5 minutes after the administration of sedative
Pruritus
Severity of pruritus. Pruritus will be assessed by a four-point ordinal scale where zero points to no itching, one points to mild itching, two points to moderate itching, treatment not requested, three points to severe itching, treatment requested.
Measured: during procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Mar 2022
- Study start1 Jul 2022
- Primary completion20 Sep 2022
- Study completion1 Oct 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ShiveringStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The assigned medication will be prepared in a color coded 250 ml polypropylene bottle of normal saline. The administration of the assigned infusion will be done by a resident not involved in the study after stabilization of the sensory blockade level over a duration of 15 to 20 minutes, the study drugs will be prepared by the hospital pharmacy and follow-up of the patients will be conducted by the anesthesia residents not involved in any other part of the study. Group A: (control group) 36 patients will receive 0.5 mg/kg Pethidine IVI for management of shivering induced by Single Shot Spinal Anesthesia. Group B: 36 patients will receive 15 mg/kg Acetaminophen IVI for management of shivering induced by Single Shot Spinal Anesthesia. Group C: 36 patients will receive 0.1 mg/kg Dexamethasone IVI for management of shivering induced by Single Shot Spinal Anesthesia.
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 130 participants (actual)
Sponsor and investigators
- Lead sponsor
- Ain Shams University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Nouh, Ain Shams University
- Investigators
- Galal A Al Kadi, MD, Study director, Professor of Anesthesia
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05284409
- Sponsor's protocol ID
- ADP
- Status last verified
- Jan 2025
- First submitted
- 28 Feb 2022
- Last updated
- 29 Jan 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Jan 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Study Between the Prophylactic Intravenous Administrations of Acetaminophen vs Dexamethasone vs Pethidine Regarding the Incidence of Shivering Induced by Single Shot Spinal Anesthesia in the Orthopedic Surgeries of the Lower Limbs
- ClinicalTrials.gov ID
- NCT05284409
- Acronym / sponsor ID
- ADP
- Conditions
- Shivering
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 130 participants (actual)
- Lead sponsor
- Ain Shams UniversityUniversity, hospital or other
- Study start
- 1 Jul 2022 (actual)
- Primary completion
- 20 Sep 2022 (actual)
- Study completion
- 1 Oct 2022 (actual)
- First posted
- 17 Mar 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Single Shot Spinal anesthesia (SSSA) is associated with considerable perioperative shivering and can be challenging to treat. Some pharmacologic agents like N-methyl d-aspartate receptor antagonists, magnesium sulfate and opioid analgesics have been used for restriction of post-spinal anesthesia shivering. Besides that shivering is poorly understood, the gold standard for the treatment and prevention has not been defined yet.
This study is to determine the effect of prophylactic intravenous administration of acetaminophen versus dexamethasone versus pethidine in controlling shivering induced by spinal anesthesia
Detailed description
Aim of this study is to compare between the prophylactic intravenous administrations of acetaminophen vs dexamethasone vs pethidine regarding the incidence of shivering induced by single shot spinal anesthesia in the orthopedic surgeries of the lower limbs
Ethical Considerations: Approval of the research ethical committee of the faculty of medicine, Ain Shams University will be obtained and informed written consents will be taken from all the participants after full clarification of the study and their rights for withdrawal at any time will be assured and their privacy will be guaranteed. The single shot spinal anesthesia technique will be performed by a single experienced anesthetist.
Study tools: Bedside Shivering Assessment Scale (BSAS) to indicate the degree of shivering at the time of its onset either intra or postoperatively, and throughout the duration of one hour at the post-anesthesia care unit (PACU).
Study Interventions: The study will include 108 patients fulfilling the inclusion criteria undergoing orthopedic surgeries of the lower limbs. The patients will be randomized into three equal groups by a computer-generated table of random numbers, each including 36 patients, namely groups A, B, and C according to the drug used as an anti-shivering agent. The assigned medication will be prepared in a color coded 250 ml polypropylene bottle of normal saline. The administration of the assigned infusion will be done by a resident not involved in the study after stabilization of the sensory blockade level over a duration of 15 to 20 minutes, the study drugs will be prepared by the hospital pharmacy and follow-up of the patients will be conducted by the anesthesia residents not involved in any other part of the study.
Group A: (control group) 36 patients will receive 0.5 mg/kg Pethidine IVI for management of shivering induced by Single Shot Spinal Anesthesia.
Group B: 36 patients will receive 15 mg/kg Acetaminophen IVI for management of shivering induced by Single Shot Spinal Anesthesia.
Group C: 36 patients will receive 0.1 mg/kg Dexamethasone IVI for management of shivering induced by Single Shot Spinal Anesthesia.
All patients will be assessed preoperatively, and will be instructed to fast for 6 hours.
On arrival to the operating theatre, all patients will have an inserted peripheral wide bore IV access (18 G). Anti-stress measures: intravenous pantoprazole 40 mg will be given. I.V. fluids will be preheated to room temperature. Lactated Ringer's solution will be infused at 10 ml/kg over 30 min before spinal anesthesia. The infusion rate will then be modified according to the intraoperative fluid balance.
Conventional monitoring including electrocardiogram (ECG), heart rate (HR), non-invasive blood pressure (NIBP) and pulse oximetry (SPO2) will be conducted. Hemodynamic readings (Mean arterial blood pressure (MAP), HR, and SPO2), peripheral and room temperatures will be recorded before the administration of the single shot spinal anesthesia. The operating and recovery rooms temperatures will be maintained at 25°C±1 with approximately 60% humidity.
Preoperatively, all of the patients will receive titration of 0.5 mg Midazolam increments on intravenously as an anesthetic adjuvant. Anesthetic equipment and drugs for resuscitation will be kept ready at hand before starting the spinal anesthesia. Supplemental oxygen (6 liter/min) will be administered via a facemask during the operation.
The patients in all of the groups will receive SSSA. The blocks will be performed by well trained personnel. The blocks will be performed before administration of the compared medications after obtaining intravenous (IV) access and application of standard ASA monitoring. Under complete aseptic conditions, single shot spinal anesthesia will be instituted at either L3/4 or L4/5 interspaces. 2.8 mL (14 mg) of 0.5% hyperbaric bupivacaine at a rate of 0.2 ml/sec will be injected in the sitting position by an anesthetist who was blind to the study by using 25 gauge Quincke spinal needle. The patient will be placed in the Supine position. The sensory blockade level will be checked in order not to reach the level of T4.
Sensory levels will be assessed by pinprick test to determine the peak sensory level and time to two segment regression in minutes. Motor block will be assessed by using Modified Bromage scale (16) (0 = no block 1 = hip block, 2 = hip and knee block, 3 = hip, knee, and ankle block) to determine the time to reach complete motor block and duration of motor blockade (in minutes).
The desired motor and sensory block will be Bromage scale 3 and T6, respectively.
All of the patients will be covered with one layer of surgical drapes over the chest, thighs, and calves during the operation and one cotton blanket over the entire body after operation. Assessment parameters: HR, MAP, and SPO2 will be recorded using standard non-invasive monitors before intrathecal injection and thereafter at 5, 10, 15, 20 minutes then every 10 minutes to complete 90 minutes from the intrathecal injection.
All of the patients will be observed for: Hypotension (defined as a decrease in MAP of more than 20% from baseline or a decrease of the systolic arterial blood pressure below 90 mmHg and baseline MAP will be calculated from three measurements taken in the ward before the operation) will be treated by crystalloid infusion and if necessary ephedrine 5 mg IV will be administered. The amount of ephedrine given in each group will be recorded. Bradycardia will be considered if the heart rate is less than 50 beats/min and will be treated with IV atropine (0.01mg/kg).
Pruritus will be assessed by a four-point ordinal scale where zero points to no itching, one points to mild itching, two points to moderate itching, treatment not requested, three points to severe itching, treatment requested.
In case of pruritus (45.5 mg intramuscular pheniramine hydrogen maleate) will be given.
The administration of the assigned infusion will be done by a resident not involved in the study after stabilization of the sensory blockade level over the duration of 15 to 20 minutes.
The level of sedation will be assessed according to a five-point range: [1] alert and oriented, [2] somnolent, [3] closed eyes, arousable on a verbal order, [4] closed eyes, arousable to physical stimuli and [5] closed eyes and patient unarousable to physical stimuli.
Body temperature (axillary temperature) will be recorded with a percutaneous thermometer. The ambient temperature will be measured by a wall thermometer. The ambient temperature will be maintained at 25 degree Celsius with constant humidity. Fluid management intraoperatively will be done according to bodyweight of the patient and intra-operative losses.
When shivering occurs, it will be graded using Bedside Shivering Assessment Scale (BSAS): 0 - None: No Shivering, 1 - Mild: Shivering localized to neck/thorax, maybe seen only as artifact on ECG or felt by palpation 2 - Moderate: Intermittent involvement of the upper extremities +/- thorax 3 -Severe: Generalized shivering or sustained upper / lower extremity shivering.
In all of the groups, the degree of shivering will be assessed at the time of its onset either intra or postoperatively, and throughout the duration of one hour at the post-anesthesia care unit (PACU). Grade 3 or 4 of shivering score will be regarded as failure of prophylaxis, and a rescue dose of 0.2 mg/kg Pethidine IV will be administered and the total dose will be recorded.
Patients will be admitted to the PACU. Patient's satisfaction will be assessed by asking the patient to answer the question, "How would you rate your experience after the operation?" using a 7-point Likert verbal rating scale, and acceptable satisfaction score of the patient will range from 5 to 7 (1 - Extremely dissatisfied, 2 - Dissatisfied, 3 - Somewhat dissatisfied, 4 - Undecided, 5 - Somewhat satisfied, 6 - Satisfied, 7 - Extremely satisfied).
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 3
- Model description
- The assigned medication will be prepared in a color coded 250 ml polypropylene bottle of normal saline. The administration of the assigned infusion will be done by a resident not involved in the study after stabilization of the sensory blockade level over a duration of 15 to 20 minutes, the study drugs will be prepared by the hospital pharmacy and follow-up of the patients will be conducted by the anesthesia residents not involved in any other part of the study. Group A: (control group) 36 patients will receive 0.5 mg/kg Pethidine IVI for management of shivering induced by Single Shot Spinal Anesthesia. Group B: 36 patients will receive 15 mg/kg Acetaminophen IVI for management of shivering induced by Single Shot Spinal Anesthesia. Group C: 36 patients will receive 0.1 mg/kg Dexamethasone IVI for management of shivering induced by Single Shot Spinal Anesthesia.
| Arm | Type | Receives |
|---|---|---|
| Pethidine | Active comparator | Drug: Pethidine(control group) 36 patients will receive 0.5 mg/kg Pethidine IVI for management of shivering induced by Single Shot Spinal Anesthesia. |
| Acetaminophen | Experimental | Drug: Acetaminophen36 patients will receive 15 mg/kg Acetaminophen IVI for management of shivering induced by Single Shot Spinal Anesthesia. |
| Dexamethasone | Experimental | Drug: Dexamethasone36 patients will receive 0.1 mg/kg Dexamethasone IVI for management of shivering induced by Single Shot Spinal Anesthesia. |
Who may qualify
- Ages
- 20 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- American Society of Anesthesiologists physical status (ASA) I or II.
- Both sexes.
- Age ranging from 20 to 55 years old.
- Body weight ranging from 60 to 100 kilograms.
- Receiving Single Shot Spinal anesthesia.
Key exclusion criteria (10 listed)
- Patient's refusal.
- Allergy to local anesthetics or any of the studied drugs.
- Patients with significant cognitive dysfunction.
- Duration of surgery more than 120 min.
- Patients with hypo- or hyperthyroidism.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Pethidine36 patients will receive 0.5 mg/kg Pethidine IVI | Drug | Pethidine |
| Acetaminophen36 patients will receive 15 mg/kg Acetaminophen IVI | Drug | Acetaminophen |
| Dexamethasone36 patients will receive 0.1 mg/kg Dexamethasone IVI | Drug | Dexamethasone |
Primary outcome
The incidence of shivering
Time frame: During procedure to up to one hour at the post-anesthesia care unit (PACU)
The incidence of shivering induced by single shot spinal anesthesia after the prophylactic administration of the study medications. When shivering occurs, it will be graded using Bedside Shivering Assessment Scale (BSAS): 0 - None: No Shivering, 1 - Mild: Shivering localized to neck/thorax, maybe seen only as artifact on ECG or felt by palpation 2 - Moderate: Intermittent involvement of the upper extremities +/- thorax 3 -Severe: Generalized shivering or sustained upper / lower extremity shivering. In all of the groups, the degree of shivering will be assessed at the time of its onset either intra or postoperatively, and throughout the duration of one hour at the post-anesthesia care unit (PACU). Grade 3 or 4 of shivering score will be regarded as failure of prophylaxis, and a rescue dose of 0.2 mg/kg Pethidine IV will be administered and the total dose will be recorded.
5 secondary outcomes
The need to administer pethidine
Time frame: The time of administration of pethidine
the total dose of Pethidine given
Time frame: The time of administration of pethidine
The patient's satisfaction
Time frame: up to one hour postoperative
The level of sedation
Time frame: within 5 minutes after the administration of sedative
Pruritus
Time frame: during procedure
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Jan 2025.
- Individual participant dataSharing planned: No
Related trials for Shivering
Recruiting
Effect Of Acupressure On Hypothermıa And Shıverıng After Cesarean Sectıon
Hypothermia, Shivering
Not yet recruitingPhase 4
Effect of Preoperative Intranasal Dexmedetomidine on Incidence of Intraoperative Shivering in Patients Undergoing Cesarean Section Under Spinal Anesthesia
Shivering, Hypothermia
Not yet recruitingPhase 4
Optimizing the Paracetamol Dose for Prevention of Post-Spinal Shivering in Lower Limb Orthopedic Surgeries
Shivering, Postoperative Shivering
Not yet recruitingPhase 4
Efficacy of Intravenous Midazolam-Ketamine Combination Versus Placebo for Prevention of Post-Spinal Shivering in Elective Cesarean Section
Shivering, Post-Spinal Shivering
Not yet recruitingPhase 4
Intravenous Paracetamol Versus Magnesium Sulfate for Control of Shivering Following Spinal Anesthesia in Cesarean Section
Shivering, Post-Spinal Shivering
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Galal A Al Kadi, MD study director
Professor of Anesthesia
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Pethidine, Acetaminophen and Dexamethasone in people with Shivering, run by Ain Shams University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The incidence of shivering (time frame: During procedure to up to one hour at the post-anesthesia care unit (PACU)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jan 2025.